

Protein Phosphatase Therapeutic Pipeline Market Review, H1 2016

Protein Phosphatase Treatment Pipeline Review H1 2016

PUNE, INDIA, October 5, 2016

/EINPresswire.com/ -- [Protein Phosphatase 2A](#) (PP2A or EC 3.1.3.16)

'Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H2 2016', provides in depth analysis on Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted pipeline therapeutics. The report provides comprehensive information on the Protein Phosphatase 2A (PP2A or EC 3.1.3.16), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics development and features dormant and discontinued projects.



Get Sample Report @ <https://www.wiseguyreports.com/sample-request/668884-protein-phosphatase-2a-pp2a-or-ec-3-1-3-16-pipeline-review-h2-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios,

enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for Protein Phosphatase 2A (PP2A or EC 3.1.3.16)
- The report reviews Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics and enlists all their major and minor projects
- The report assesses Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics

Have any query @ <https://www.wiseguyreports.com/enquiry/668884-protein-phosphatase-2a-pp2a-or-ec-3-1-3-16-pipeline-review-h2-2016>

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Protein Phosphatase 2A (PP2A or EC 3.1.3.16)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Protein Phosphatase 2A (PP2A or EC 3.1.3.16) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents	2
List of Tables	4
List of Figures	4
Introduction	5
Global Markets Direct Report Coverage	5
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) Overview	6
Therapeutics Development	7
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Products under Development by Stage of Development	7
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Products under Development by Therapy Area	8
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Products under Development by Indication	9
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Products Glance	11
Late Stage Products	11
Early Stage Products	12
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Products under Development by Companies	13
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Therapeutics Assessment	15
Assessment by Monotherapy/Combination Products	15
Assessment by Mechanism of Action	16
Assessment by Route of Administration	18
Assessment by Molecule Type	20
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Companies Involved in Therapeutics Development	21
Ampio Pharmaceuticals, Inc.	21
Bristol-Myers Squibb Company	22
Cyano Biotech GmbH	23
Lixte Biotechnology Holdings, Inc.	24
Signum Biosciences, Inc.	25
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Drug Profiles	26
Drugs to Activate PP2A for Oncology - Drug Profile	26
Product Description	26
Mechanism Of Action	26
R&D Progress	26
DT-1154 - Drug Profile	27
Product Description	27
Mechanism Of Action	27
R&D Progress	27
LB-100 - Drug Profile	28
Product Description	28
Mechanism Of Action	28
R&D Progress	28
NCE-001 - Drug Profile	31

Product Description 31
Mechanism Of Action 31
R&D Progress 31
Small Molecules to Activate PP2A for Parkinson Disease and Alzheimer's Disease - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Small Molecules to Inhibit PP1 and PP2A for Oncology - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
VEL-015 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Dormant Projects 36
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Featured News & Press Releases 37
Continued...

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=668884 □

Follow Us:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/347919252>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.